Pioneering research by Xiong et al. determined that the selective genetic knockout of iNOS as well as NADPH oxidase inhibition with orally administered apocynin resulted in the decreased expression of MMP-2 and MMP-9, lower levels of NO2 and NO3 production, and a notable reduction in AAA formation [45]. The gene discussed is FMO5; the disease is triple-A syndrome.